Company news

NRX Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NRx Pharmaceuticals (NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17

November 13, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

November 11, 2025

NRx Pharmaceuticals (NRXP) Launches HOPE Therapeutics' One-Day TMS Protocol for Treatment-Resistant Depression in Florida

November 10, 2025

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

November 9, 2025

NRx Pharmaceuticals (NRXP) Advancing Two-Pronged Approach to Bring Innovative Therapies to Market

October 27, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

October 19, 2025

NRx Pharmaceuticals (NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

October 17, 2025

NRx Pharmaceuticals (NRXP) Strengthens Pipeline With Dual Pathways for Ketamine-Based Therapies

October 9, 2025

NRx Pharmaceuticals (NRXP) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

October 6, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

October 5, 2025

NRx Pharmaceuticals (NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)

September 30, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

September 28, 2025

NRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

September 24, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine

September 23, 2025

NRx Pharmaceuticals (NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical

September 9, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

September 7, 2025

NRx Pharmaceuticals (NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

September 3, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

September 2, 2025

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

September 1, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

September 1, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation

August 27, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

August 26, 2025

NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem

August 25, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

August 25, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs

August 19, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 17, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression

August 14, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics(TM) Secures Florida Regulatory Clearance to Close Dura Medical Acquisition

August 14, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) Petitions FDA to Ban Benzethonium Chloride From Ketamine Products

August 13, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

August 12, 2025

NRx Pharmaceuticals (NASDAQ: NRXP) CEO to Join Fireside Chat at BTIG Virtual Biotechnology Conference

August 12, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

August 10, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

August 10, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

August 7, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products

August 3, 2025

New to The Street Show #682 Premieres on Bloomberg Tonight Featuring Industry Leaders: DataVault, PetVivo, Health In Tech, FLOKI, and NRx Pharma Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team

August 1, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

July 28, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Charts Dual-Path for NRX-100

July 21, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment

July 16, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

July 8, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100

June 30, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

June 26, 2025

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

June 25, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

June 22, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 16, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

June 15, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 11, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

June 6, 2025

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine

June 5, 2025

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

June 4, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.